{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:48:43Z","timestamp":1787237323533,"version":"build-2736575974"},"reference-count":17,"publisher":"Walter de Gruyter GmbH","issue":"3","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Gastric cancer (GC) is one of the most widespread types of cancer worldwide. Helicobacter pylori infection has been clearly correlated with gastric carcinogenesis. At present and in the near future, the most important challenge is and will be the significant reduction of mortality due to GC. That goal can be achieved through the identification of higher-risk patients, such as those with atrophic gastritis, intestinal metaplasia and dysplasia. In this review we intend to discuss the importance of diagnosing H. pylori infection and chronic atrophic gastritis in preventing gastric cancer, using a new non-invasive test called GastroPanel. This test is a classification algorithm including four biochemical parameters pepsinogen I and II (PGI and PGII), gastrin-17 (G17), and anti-Helicobacter pylori antibodies (Ig G anti-Hp) measured in fasting sera, which allows to classify patients as having atrophic or non-atrophic gastritis and to find whether gastritis is associated or not with H. pylori infection. GastroPanel is not a \u201ccancer test\u201d, but it can and should be used in the screening and diagnosis of subjects with a high cancer risk; still, a careful diagnostic made by superior digestive endoscopy is compulsory to find possible precancerous or cancerous lesions at an early and curable stage.<\/jats:p>","DOI":"10.1515\/rjim-2016-0025","type":"journal-article","created":{"date-parts":[[2016,4,5]],"date-time":"2016-04-05T04:25:10Z","timestamp":1459830310000},"page":"151-156","source":"Crossref","is-referenced-by-count":13,"title":["Helicobacter pylori Infection, Gastric Cancer and Gastropanel"],"prefix":"10.1515","volume":"54","author":[{"given":"Alexandra","family":"Loor","sequence":"first","affiliation":[{"name":"\u201cIuliu Ha\u0163ieganu\u201d University of Medicine and Pharmacy, Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.L.","family":"Dumitra\u015fcu","sequence":"additional","affiliation":[{"name":"\u201cIuliu Ha\u0163ieganu\u201d University of Medicine and Pharmacy, Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2016,9,22]]},"reference":[{"key":"2021040609520066326_j_rjim-2016-0025_ref_001_w2aab2b8c11b1b7b1ab1ab1Aa","unstructured":"1. WITKOUSCA M., SMOLEWSKI P. Helicobacter pylori infection, chronic inflammation, and genomic transformations in gastric MALT lymphoma. Mediators of Inflammation. 2013; 2013:523170."},{"key":"2021040609520066326_j_rjim-2016-0025_ref_002_w2aab2b8c11b1b7b1ab1ab2Aa","unstructured":"2. CORREA P., PIAZUELO B.M. Helicobacter pylori infection and gastric adenocarcinoma. Gastroenterol Hepatol Rev. 2011; 7(1): 59-64."},{"key":"2021040609520066326_j_rjim-2016-0025_ref_003_w2aab2b8c11b1b7b1ab1ab3Aa","unstructured":"3. CORREA P. Human gastric carcinogenesis: a multistep and multifactorial process first American cancer society award lecture on cancer epidemiology and prevention. Cancer Res. 1992; 52(24):6735-40."},{"key":"2021040609520066326_j_rjim-2016-0025_ref_004_w2aab2b8c11b1b7b1ab1ab4Aa","unstructured":"4. VENERITO M., MALFERTHEINER P., Preneoplastic conditions in the stomach: always a point of no return? Dig Dis 2015; 33:5-10."},{"key":"2021040609520066326_j_rjim-2016-0025_ref_005_w2aab2b8c11b1b7b1ab1ab5Aa","doi-asserted-by":"crossref","unstructured":"5. WONG B.C., LAM S.K., WONG W.M., CHEN J.S., ZHENG T.T., FENG R.E., et al. China gastric cancer study group: Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: A randomized controlled trial. JAMA 2004; 291: 187-194.","DOI":"10.1001\/jama.291.2.187"},{"key":"2021040609520066326_j_rjim-2016-0025_ref_006_w2aab2b8c11b1b7b1ab1ab6Aa","doi-asserted-by":"crossref","unstructured":"6. PATEL S.K., PRATAB C.B., JAIN A.K., GULATI K., NATH G. Diagnosis of Helicobacter pylori: What should be the gold standard? World J Gastroenterol. 2014 Sep 28; 20(36): 12847-59.","DOI":"10.3748\/wjg.v20.i36.12847"},{"key":"2021040609520066326_j_rjim-2016-0025_ref_007_w2aab2b8c11b1b7b1ab1ab7Aa","unstructured":"7. http:\/\/www.gastropanel.com\/ Accessed 28 November 2015."},{"key":"2021040609520066326_j_rjim-2016-0025_ref_008_w2aab2b8c11b1b7b1ab1ab8Aa","doi-asserted-by":"crossref","unstructured":"8. NOAH D., ASSOUMOU M.C., BAGNAKA S.A., NGABA G.P., ALONGE I.E., PALOHEIMO L., NJOYA O., Assessing GastroPanel serum markers as a non-invasive method for the diagnosis of atrophic gastritis and Helicobacter pylori infection. Open Journal of Gastroenterology, 2012; 2:113-118.","DOI":"10.4236\/ojgas.2012.23024"},{"key":"2021040609520066326_j_rjim-2016-0025_ref_009_w2aab2b8c11b1b7b1ab1ab9Aa","doi-asserted-by":"crossref","unstructured":"9. STORKRUBB T., ARO P., RONKRAINEN J., SIPPONEN P., NYHLIN H., TALLEY NJ., et al. Serum biomarkers provide an accurate method for diagnosis of atrophic gastritis in a general population: the Kalixanda study. Scand J Gastroenterol. 2008; 43:1448-55.","DOI":"10.1080\/00365520802273025"},{"key":"2021040609520066326_j_rjim-2016-0025_ref_010_w2aab2b8c11b1b7b1ab1ac10Aa","doi-asserted-by":"crossref","unstructured":"10. LOMBARDO L., LETO R., MOLINARO G., MIGLIARDI M., RAVARINO N., ROCCAR., TORCHIO B. Prevalence of atrophic gastritis in dyspeptic patients in Piedmont. A survey using the GastroPanel test. Clin Chem Lab Med. 2010; 48(9):1327-32.","DOI":"10.1515\/cclm.2010.256"},{"key":"2021040609520066326_j_rjim-2016-0025_ref_011_w2aab2b8c11b1b7b1ab1ac11Aa","doi-asserted-by":"crossref","unstructured":"11. IIJIMA K., ABE Y., KIKUCHI R., KOIKE T.I., OHARA S., SIPPONEN P., et al. Serum biomarker tests are useful in delineating between patients with gastric atrophy and normal, healthy stomach. World J Gastroenterol. 2009; 15(7): 853-859.","DOI":"10.3748\/wjg.15.853"},{"key":"2021040609520066326_j_rjim-2016-0025_ref_012_w2aab2b8c11b1b7b1ab1ac12Aa","doi-asserted-by":"crossref","unstructured":"12. LIN J.S. Screening of gastric cancer: Who, when, and how. Clinical Gastroenterology and Hepatology 2014; 12:135-138.","DOI":"10.1016\/j.cgh.2013.09.064"},{"key":"2021040609520066326_j_rjim-2016-0025_ref_013_w2aab2b8c11b1b7b1ab1ac13Aa","doi-asserted-by":"crossref","unstructured":"13. TERASAWA T., NISHIDA H., KATO K., MIYASHIRO I., YOSHIKAWA T., TAKAKU R., et al. Prediction of gastric cancer development by serum pepsinogen test and Helicobacter pylori seropositivity in eastern Asians: A systematic review and metaanalysis. PLoS One. 2014; 9(10): e109783.","DOI":"10.1371\/journal.pone.0109783"},{"key":"2021040609520066326_j_rjim-2016-0025_ref_014_w2aab2b8c11b1b7b1ab1ac14Aa","doi-asserted-by":"crossref","unstructured":"14. CHOI H.S., LEE S-Y., KIM J.H., SUNG I-K., PARK H.S., SHIM C.S., et al. Combining the serum pepsinogen level and Helicobacter pylori antibody test for predicting the histology of gastric neoplasm. Journal of Digestive Diseases 2014; 15:293-8.","DOI":"10.1111\/1751-2980.12144"},{"key":"2021040609520066326_j_rjim-2016-0025_ref_015_w2aab2b8c11b1b7b1ab1ac15Aa","doi-asserted-by":"crossref","unstructured":"15. TU H., SUN L., DONG X., GONG Y., XU O., JING J., et al. Temporal changes in serum biomarkers and risk for progression of gastric precancerous lesions: A longitudinal study. Int J Cancer. 2015; 136(2):425-34.","DOI":"10.1002\/ijc.29005"},{"key":"2021040609520066326_j_rjim-2016-0025_ref_016_w2aab2b8c11b1b7b1ab1ac16Aa","doi-asserted-by":"crossref","unstructured":"16. YEH J.M., HUR C., WARD Z., SCHRAG D., GOLDIE S.J. Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technologies: A cost-effectiveness analysis. Gut 2016; 65(4):563-74.","DOI":"10.1136\/gutjnl-2014-308588"},{"key":"2021040609520066326_j_rjim-2016-0025_ref_017_w2aab2b8c11b1b7b1ab1ac17Aa","unstructured":"17. KIM B.C., JUNG S.W., KIM J.B., HAN A.R., JANG S., PARK S.H., et al. Serum gastrin levels in different stages of distal gastric carcinogenesis: Is there a role for serum gastrin in tumor growth? Turk J Gastroenterol 2014; 25: 611-8."}],"container-title":["Romanian Journal Of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/content.sciendo.com\/view\/journals\/rjim\/54\/3\/article-p151.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.sciendo.com\/article\/10.1515\/rjim-2016-0025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T06:02:21Z","timestamp":1617688941000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.sciendo.com\/article\/10.1515\/rjim-2016-0025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,1]]},"references-count":17,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2016,9,22]]},"published-print":{"date-parts":[[2016,9,1]]}},"alternative-id":["10.1515\/rjim-2016-0025"],"URL":"https:\/\/doi.org\/10.1515\/rjim-2016-0025","relation":{},"ISSN":["2501-062X"],"issn-type":[{"value":"2501-062X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,1]]}}}